Is SGMT or CGEM more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% Cullinan Therapeutics N/A -51.45% -47.64%

Does the media favor SGMT or CGEM?

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 1 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.94 beat Sagimet Biosciences' score of 0.80 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or SGMT more profitable?

Janux Therapeutics' return on equity of -12.93% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Sagimet Biosciences N/A -37.57% -35.52%

Is ANNX or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Sagimet Biosciences N/A -37.57% -35.52%

Does the media refer more to ANNX or SGMT?

In the previous week, Annexon had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Annexon and 1 mentions for Sagimet Biosciences. Annexon's average media sentiment score of 1.29 beat Sagimet Biosciences' score of 0.80 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sagimet Biosciences (SGMT) Competitors

$7.06 +0.20 (+2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$7.06 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

SGMT vs. CGEM, PHAT, ABUS, JANX, and ANNX

Should you buy Sagimet Biosciences stock or one of its competitors? MarketBeat compares Sagimet Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sagimet Biosciences include Cullinan Therapeutics (CGEM), Phathom Pharmaceuticals (PHAT), Arbutus Biopharma (ABUS), Janux Therapeutics (JANX), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Sagimet Biosciences (NASDAQ:SGMT) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Sagimet Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sagimet Biosciences has higher revenue and earnings than Cullinan Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 1 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.94 beat Sagimet Biosciences' score of 0.80 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences presently has a consensus target price of $25.75, suggesting a potential upside of 264.73%. Cullinan Therapeutics has a consensus target price of $30.75, suggesting a potential upside of 113.10%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sagimet Biosciences' return on equity of -37.57% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Summary

Sagimet Biosciences beats Cullinan Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Sagimet Biosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Phathom Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market.

Phathom Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 153.55%. Sagimet Biosciences has a consensus target price of $25.75, indicating a potential upside of 264.73%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sagimet Biosciences has lower revenue, but higher earnings than Phathom Pharmaceuticals. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.49	-$221.25M	-$2.12	N/A
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

In the previous week, Sagimet Biosciences had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.87 beat Sagimet Biosciences' score of 0.80 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Sagimet Biosciences	Positive

Summary

Sagimet Biosciences beats Phathom Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Sagimet Biosciences had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.89 beat Sagimet Biosciences' score of 0.80 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Very Positive
Sagimet Biosciences	Positive

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 14.94%. Sagimet Biosciences has a consensus price target of $25.75, suggesting a potential upside of 264.73%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arbutus Biopharma has a net margin of 83.95% compared to Sagimet Biosciences' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Arbutus Biopharma has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arbutus Biopharma has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market.

Summary

Arbutus Biopharma beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Janux Therapeutics' return on equity of -12.93% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Sagimet Biosciences has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	83.91	-$113.62M	-$1.84	N/A
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market.

Janux Therapeutics currently has a consensus target price of $45.85, indicating a potential upside of 233.18%. Sagimet Biosciences has a consensus target price of $25.75, indicating a potential upside of 264.73%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sagimet Biosciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.43 beat Sagimet Biosciences' score of 0.80 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Positive
Sagimet Biosciences	Positive

Summary

Sagimet Biosciences beats Janux Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Sagimet Biosciences compare to Annexon?

Annexon (NASDAQ:ANNX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

87.9% of Sagimet Biosciences shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sagimet Biosciences' return on equity of -37.57% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

In the previous week, Annexon had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Annexon and 1 mentions for Sagimet Biosciences. Annexon's average media sentiment score of 1.29 beat Sagimet Biosciences' score of 0.80 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon currently has a consensus target price of $16.00, indicating a potential upside of 193.58%. Sagimet Biosciences has a consensus target price of $25.75, indicating a potential upside of 264.73%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sagimet Biosciences has higher revenue and earnings than Annexon. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Sagimet Biosciences	$2M	115.01	-$51.04M	-$1.34	N/A

Summary

Sagimet Biosciences beats Annexon on 10 of the 14 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$230.02M	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-5.27	18.72	23.87	24.40
Price / Sales	115.01	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	2.06	6.80	9.99	6.73
Net Income	-$51.04M	$24.09M	$3.56B	$337.03M
7 Day Performance	-2.89%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	73.04%	48.95%	28.77%	34.24%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	3.8135 of 5 stars	$7.06 +2.9%	$25.75 +264.7%	+89.0%	$230.02M	$2M	N/A	8	News Coverage
CGEM Cullinan Therapeutics	3.5645 of 5 stars	$15.07 +8.9%	$30.75 +104.0%	+69.8%	$926.20M	N/A	N/A	30	Gap Up
PHAT Phathom Pharmaceuticals	2.7537 of 5 stars	$11.25 -0.7%	$25.00 +122.2%	+103.8%	$897.30M	$175.11M	N/A	110
ABUS Arbutus Biopharma	2.3876 of 5 stars	$4.49 +3.2%	$5.00 +11.4%	+26.1%	$886.96M	$14.08M	5.41	90
JANX Janux Therapeutics	3.5965 of 5 stars	$14.51 -0.1%	$45.85 +216.0%	-46.6%	$884.82M	$10M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. CGEM, PHAT, ABUS, JANX, and ANNX

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Summary

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Arbutus Biopharma?

Summary

How does Sagimet Biosciences compare to Janux Therapeutics?

Summary

How does Sagimet Biosciences compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. CGEM, PHAT, ABUS, JANX, and ANNX

How does Sagimet Biosciences compare to Cullinan Therapeutics?

Which has more volatility and risk, SGMT or CGEM?

Do institutionals and insiders have more ownership in SGMT or CGEM?

Which has stronger valuation and earnings, SGMT or CGEM?

Does the media favor SGMT or CGEM?

Do analysts prefer SGMT or CGEM?

Is SGMT or CGEM more profitable?

Summary

How does Sagimet Biosciences compare to Phathom Pharmaceuticals?

Is PHAT or SGMT more profitable?

Which has more volatility & risk, PHAT or SGMT?

Do analysts prefer PHAT or SGMT?

Do institutionals & insiders believe in PHAT or SGMT?

Which has better earnings and valuation, PHAT or SGMT?

Does the media favor PHAT or SGMT?

Summary

How does Sagimet Biosciences compare to Arbutus Biopharma?

Does the media refer more to ABUS or SGMT?

Do analysts recommend ABUS or SGMT?

Is ABUS or SGMT more profitable?

Which has stronger earnings & valuation, ABUS or SGMT?

Do institutionals and insiders hold more shares of ABUS or SGMT?

Which has more volatility & risk, ABUS or SGMT?

Summary

How does Sagimet Biosciences compare to Janux Therapeutics?

Is JANX or SGMT more profitable?

Which has preferable valuation & earnings, JANX or SGMT?

Do insiders and institutionals believe in JANX or SGMT?

Which has more volatility and risk, JANX or SGMT?

Do analysts rate JANX or SGMT?

Does the media refer more to JANX or SGMT?

Summary

How does Sagimet Biosciences compare to Annexon?

Do institutionals and insiders believe in ANNX or SGMT?

Is ANNX or SGMT more profitable?

Which has more risk and volatility, ANNX or SGMT?

Does the media refer more to ANNX or SGMT?

Do analysts rate ANNX or SGMT?

Which has higher valuation and earnings, ANNX or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools